Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 462.3 DKK 0.48%
Market Cap: 33B DKK

Zealand Pharma A/S
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zealand Pharma A/S
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Stock-Based Compensation
kr110.6m
CAGR 3-Years
62%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Stock-Based Compensation
kr115.6m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Stock-Based Compensation
€112.4m
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
53%
B
Bavarian Nordic A/S
CSE:BAVA
Stock-Based Compensation
kr83.9m
CAGR 3-Years
33%
CAGR 5-Years
23%
CAGR 10-Years
12%
Bioporto A/S
CSE:BIOPOR
Stock-Based Compensation
kr1.1m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Saniona AB
STO:SANION
Stock-Based Compensation
kr3.7m
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Zealand Pharma A/S
Glance View

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
759.97 DKK
Undervaluation 39%
Intrinsic Value
Price

See Also

What is Zealand Pharma A/S's Stock-Based Compensation?
Stock-Based Compensation
110.6m DKK

Based on the financial report for Sep 30, 2025, Zealand Pharma A/S's Stock-Based Compensation amounts to 110.6m DKK.

What is Zealand Pharma A/S's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
62%

Over the last year, the Stock-Based Compensation growth was 44%. The average annual Stock-Based Compensation growth rates for Zealand Pharma A/S have been 62% over the past three years .

Back to Top